newsmetry
rusign inget started
macro

RBC Capital keeps Outperform on Abbott Labs with $125 target

RBC Capital kept its Outperform rating on Abbott Laboratories with a $125 price target, implying 24.4% upside from the October 21 close of $100.51.

published on Newsmetry
original source published

the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →

Newsmetry newsroom

what happened

RBC Capital maintained its Outperform rating on Abbott Laboratories and set a price target of $125 per share. TradingView, citing Benzinga data, reports that the target implies 24.4% upside from the $100.51 close on October 21.

The analyst note points to a strong pipeline of new products, including Volt and Tactiflex Duo, which are expected to drive growth in the electrophysiology franchise. Combined with expected growth acceleration in 2027, RBC sees this as strengthening the company's position.

The planned separation of the nutrition business is also viewed positively, as RBC believes it will enhance growth and margins at the remaining company.

why it matters

This is one bank's analyst forecast, not a decision by the company itself. Plans to separate the nutrition business could shape investor expectations for the stock's value, but the rating applies to this single share only.

tags

Analyst RatingStockUnited States

instruments

ABT

sources

  1. RBC Capital maintains Outperform rating on Abbott Laboratories, $125 price target — TradingView, 22 October 2026 at 15:38 UTC
  2. RBC Capital maintains Outperform rating on Annaly Capital Management, $21 price target — TradingView, 22 October 2026 at 15:45 UTC
  3. RBC Capital maintains Outperform rating on AEVEX, $22 price target — TradingView, 22 October 2026 at 15:43 UTC
  4. RBC Capital maintains Outperform rating on CSX, $54 price target — TradingView, 22 October 2026 at 15:51 UTC
  5. RBC Capital reiterates Outperform rating on IBM, $270 price target — TradingView, 22 October 2026 at 15:56 UTC
  6. RBC Capital maintains Outperform rating on Meta Platforms, $800 price target — TradingView, 22 October 2026 at 16:01 UTC
  7. RBC Capital maintains Outperform rating on Pegasystems, $40 price target — TradingView, 22 October 2026 at 16:04 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.

get stories in real time ↗

related stories